Skip to main content
Pfizer, Astellas' Xtandi OK'd for second prostate cancer variant
7/16/2018

The FDA approved Pfizer and Astellas Pharma's Xtandi, or enzalutamide, as a treatment for men with non-metastatic castration-resistant prostate cancer. The drug was previously approved to treat metastatic castration-resistant prostate cancer.

Full Story: